PDE3A Is a Highly Expressed Therapy Target in Myxoid LiposarcomaKirsi Toivanen, Harri Sihto|Cancers|2023Cited by 6
Pharmacokinetic profile and <i>in vivo</i> anticancer efficacy of anagrelide administered subcutaneously in rodentsKirsi Toivanen, Harri Sihto|Drug Delivery|2025Cited by 4
Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitorsKirsi Toivanen, Harri Sihto|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Therapeutic opportunity of phosphodiesterase 3A modulators in myxoid liposarcomasKirsi Toivanen, Harri Sihto|Research Square|2022Cited by 0